{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:07:42Z","timestamp":1790248062647,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia (ATL) develops in a small proportion of individuals infected with the retrovirus human T-cell leukemia virus (HTLV-1). We evaluated the efficacy of MEDI-507 (a humanized monoclonal antibody directed against CD2) alone and in combination with humanized anti-Tac (HAT) directed toward CD25, the interleukin-2 receptor \u03b1 (IL-2R\u03b1) using a human adult T-cell leukemia xenograft model. Weekly treatments (4) with HAT significantly prolonged the survival of the ATL-bearing mice when compared with phosphate-buffered saline (PBS)\u2013treated controls (P &amp;lt; .0001). Mice treated with MEDI-507 (100 \u03bcg\/wk for 4 weeks) survived longer than those treated with HAT (P &amp;lt; .0025). Furthermore, prolonged treatment (6 months) of ATL with MEDI-507 significantly improved the outcome when compared with a short course (4 weeks) of therapy (P &amp;lt; .0036). Such treatment with weekly MEDI-507 for 6 months led to a prolonged survival of the ATL-bearing mice that was comparable with the survival observed in the control group of mice that did not receive a tumor or therapeutic agent. We also found that the expression of Fc\u03b3 receptors (FcR\u03b3) on polymorphonuclear leukocytes and monocytes was required for MEDI-507\u2013mediated tumor killing in vivo. Thus, the tumor-killing mechanism with MEDI-507 in vivo required the expression of the receptor FcR\u03b3III on polymorphonuclear leukocytes and monocytes, suggesting that it is mediated by a form of antibody-dependent cellular cytotoxicity. These results demonstrate that MEDI-507 has therapeutic efficacy on ATL in vivo and provides support for a clinical trial involving this monoclonal antibody in the treatment of patients with CD2-expressing leukemias and lymphomas. (Blood. 2003; 102:284-288)<\/jats:p>","DOI":"10.1182\/blood-2002-11-3601","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T01:50:10Z","timestamp":1048557010000},"page":"284-288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507"],"prefix":"10.1182","volume":"102","author":[{"given":"Zhuo","family":"Zhang","sequence":"first","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Ravetch","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Goldman","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218041596200_REF1","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematological features of 16 cases. Blood.1977;50: 481-492.","DOI":"10.1182\/blood.V50.3.481.481"},{"key":"2020021218041596200_REF2","doi-asserted-by":"crossref","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol.1991;79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2020021218041596200_REF3","doi-asserted-by":"crossref","unstructured":"Gill PS, Harrington WJ, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med.1995;332: 1744-1748.","DOI":"10.1056\/NEJM199506293322603"},{"key":"2020021218041596200_REF4","unstructured":"Phillips KE, Herring B, Wilson LA, et al. IL-2R-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2R\u03b1 interaction. Cancer Res.2000;60: 6977-6984."},{"key":"2020021218041596200_REF5","doi-asserted-by":"crossref","unstructured":"Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood.2002;100: 208-216.","DOI":"10.1182\/blood-2002-01-0107"},{"key":"2020021218041596200_REF6","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res.2002;62: 1083-1086."},{"key":"2020021218041596200_REF7","unstructured":"Janeway CA, Travers P, Walport M, Shlomchik MJ. The development and survival of lymphocytes. In: Austin P, Lawrence E, eds. Immunobiology: The Immune System in Health and Disease. Garland Publishing: New York, NY; 2001: 221-293."},{"key":"2020021218041596200_REF8","doi-asserted-by":"crossref","unstructured":"Kamoun M, Martin PJ, Brown MA, Siadak AW, Nowinski RC. Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med.1981;153: 207-212.","DOI":"10.1084\/jem.153.1.207"},{"key":"2020021218041596200_REF9","doi-asserted-by":"crossref","unstructured":"Bernard A, Gelin C, Raynal B, et al. Phenomena of human T cells rosetting with sheep erythrocytes analyzed with monoclonal antibodies: \u201cmodulation\u201d of a partially hidden epitope determining the conditions of interaction between T cells and erythrocytes. J Exp Med.1982;155: 1317-1333.","DOI":"10.1084\/jem.155.5.1317"},{"key":"2020021218041596200_REF10","doi-asserted-by":"crossref","unstructured":"Alberola-Ila J, Places L, de la Calle O, et al. Stimulation through the TCR\/CD3 complex up-regulates the CD2 surface expression on human T lymphocytes. J Immunol.1991;146: 1085-1092.","DOI":"10.4049\/jimmunol.146.4.1085"},{"key":"2020021218041596200_REF11","doi-asserted-by":"crossref","unstructured":"Arulanandam AR, Kister A, McGregor MJ, et al. Interaction between human CD2 and CD58 involves the major beta sheet surface of each of their respective adhesion domains. J Exp Med.1994;180: 1861-1871.","DOI":"10.1084\/jem.180.5.1861"},{"key":"2020021218041596200_REF12","doi-asserted-by":"crossref","unstructured":"Selvaraj P, Plunkett ML, Dustin M, et al. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature.1987;326: 4000-4003.","DOI":"10.1038\/326400a0"},{"key":"2020021218041596200_REF13","doi-asserted-by":"crossref","unstructured":"Ohno H, Ushiyama C, Taniguchi M, Germain RN, Saito T. CD2 can mediate TCR\/CD3-independent T cell activation. J Immunol.1991;146: 3742-3746.","DOI":"10.4049\/jimmunol.146.11.3742"},{"key":"2020021218041596200_REF14","doi-asserted-by":"crossref","unstructured":"Danielian S, Alcover A, Polissard L, et al. T cell receptor (TcR)-CD3 complex and CD2 increase the tyrosine kinase activity of p56lck: CD2 can mediate TcR-CD3-independent and CD45-dependent activation of p56lck. Eur J Immunol.1992; 22: 2915-2921.","DOI":"10.1002\/eji.1830221124"},{"key":"2020021218041596200_REF15","doi-asserted-by":"crossref","unstructured":"Latinne D, De La Parra B, Nizet Y, et al. An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro. Int Immunol.1996;8: 1113-1119.","DOI":"10.1093\/intimm\/8.7.1113"},{"key":"2020021218041596200_REF16","doi-asserted-by":"crossref","unstructured":"Dumont C, Deas O, Mollereau B, et al. Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells. J Immunol.1998;160: 3797-3804.","DOI":"10.4049\/jimmunol.160.8.3797"},{"key":"2020021218041596200_REF17","doi-asserted-by":"crossref","unstructured":"Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation.1999;68: 1588-1596.","DOI":"10.1097\/00007890-199911270-00026"},{"key":"2020021218041596200_REF18","doi-asserted-by":"crossref","unstructured":"Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood.1998;92: 4066-4071.","DOI":"10.1182\/blood.V92.11.4066"},{"key":"2020021218041596200_REF19","doi-asserted-by":"crossref","unstructured":"Sorbera LA, Leeson PA, Revel L, Bayes M. Siplizumab, MEDI-507, antipsoriatic and treatment of transplant rejection. Drugs of the Future.2002; 27: 558-562.","DOI":"10.1358\/dof.2002.027.06.679038"},{"key":"2020021218041596200_REF20","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood.1993;82: 1701-1712.","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"2020021218041596200_REF21","doi-asserted-by":"crossref","unstructured":"Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A.1998;95: 652-656.","DOI":"10.1073\/pnas.95.2.652"},{"key":"2020021218041596200_REF22","doi-asserted-by":"crossref","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med.2000;6: 443-446.","DOI":"10.1038\/74704"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/284\/1688795\/h81303000284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/284\/1688795\/h81303000284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:19:28Z","timestamp":1682468368000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/1\/284\/16835\/Effective-therapy-for-a-murine-model-of-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-11-3601","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}